高危前列腺癌术后中度大分割放疗的长期毒性与疾病控制:前瞻性研究结果
该前瞻性队列研究纳入278例术后接受中度大分割放疗(62.75 Gy/25次)的前列腺癌患者,中位随访50个月。4年晚期≥2级泌尿毒性累积发生率为28.4%,≥2级胃肠道毒性仅1.4%,4年无事件生存率81.0%、生化无进展生存率86.9%。膀胱V60Gy>12.35%与晚期≥2级血尿升高相关,放疗前2-3级尿失禁与晚期≥2级尿失禁升高相关。
要点
- 术后中度大分割放疗晚期≥2级泌尿毒性4年累积发生率28.4%,且2年后仍持续进展。
- 膀胱V60Gy>12.35%者4年晚期≥2级血尿发生率显著更高(16.3% vs 6.8%)。
- 放疗前2-3级尿失禁者4年晚期≥2级尿失禁发生率更高(31.2% vs 19.1%)。
核心结论
- 前列腺癌术后中度大分割放疗毒性可接受且疗效良好,但晚期泌尿毒性在2年后仍持续进展。
- 限制膀胱V60Gy可能减少血尿,放疗前尿失禁可预测尿失禁加重。
研究设计与样本
- 前瞻性队列研究,2018至2020年纳入278例接受术后中度大分割放疗(62.75 Gy/25次)的前列腺癌患者。
- 采用CTCAE v4.0分级晚期泌尿和胃肠道毒性,中位随访50个月。
- 分析无事件生存、生化无进展生存、疾病特异生存和总生存,并用Cox回归识别晚期泌尿毒性预测因素。
主要发现
- 晚期≥2级泌尿毒性2年和4年累积发生率分别为19.5%和28.4%。
- 膀胱V60Gy>12.35%者4年晚期≥2级血尿发生率为16.3%,对照组为6.8%(p=0.020)。
- 放疗前2-3级尿失禁者4年晚期≥2级尿失禁发生率为31.2%,无该因素者为19.1%(p=0.025)。
- 40例放疗后接受膀胱镜检查者≥2级尿失禁发生率高于未检查者(45.0% vs 17.5%,p<0.001)。
- 晚期≥2级胃肠道毒性仅4例(1.4%);4年无事件生存率81.0%、生化无进展生存率86.9%、疾病特异生存率99.6%、总生存率97.2%。
关键数值与推荐
- 术后中度大分割放疗剂量为62.75 Gy分25次。
- 膀胱V60Gy>12.35%与4年晚期≥2级血尿升高相关(16.3% vs 6.8%,p=0.020)。
- 放疗前2-3级尿失禁与4年晚期≥2级尿失禁升高相关(31.2% vs 19.1%,p=0.025)。
- 放疗后膀胱镜检查者≥2级尿失禁发生率高于未检查者(45.0% vs 17.5%,p<0.001)。
临床怎么用
- 术后中度大分割放疗可用于前列腺癌患者,但需长期监测晚期泌尿毒性。
- 计划设计时关注膀胱V60Gy,可能有助于降低晚期血尿风险。
- 对放疗前已有2-3级尿失禁的患者应加强预警和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderately hypofractionated radiation therapy (MHRT) offers practical advantages for postoperative prostate cancer (PC) patients. However, concerns persist regarding long-term genitourinary (GU) toxicity. This prospective cohort study aims to evaluate late toxicities, disease control outcomes, and to identify predictors of late GU toxicity following MHRT. METHODS: We prospectively enrolled 278 PC patients treated with postoperative MHRT (62.75 Gy delivered in 25 fractions) at our institution from 2018 to 2020. Late GU and gastrointestinal (GI) toxicities were graded using CTCAE v.4.0. Clinical outcomes were analyzed, including event-free survival (EFS), biochemical progression-free survival (bPFS), disease-specific survival (DSS), and overall survival (OS). Univariate and multivariate Cox regression analyses were performed to identify predictors associated with late GU toxicity. RESULTS: The median follow-up was 50 months. The cumulative incidence of late grade ≥ 2 GU toxicity at 2 and 4 years was 19.5% and 28.4%, respectively. Patients with bladder V60Gy > 12.35% had a significantly higher 4-year incidence of late grade ≥ 2 hematuria (16.3% vs. 6.8%, p = 0.020). Furthermore, the 4-year cumulative incidence of late grade ≥ 2 urinary incontinence (UI) was higher in patients with preRT grade 2-3 incontinence (31.2% vs. 19.1%, p = 0.025). Among 40 patients undergoing postRT cystoscopy, these patients experienced significant higher rates of grade ≥ 2 UI than those not undergoing cystoscopy (45.0% vs. 17.5%, p < 0.001). Late grade ≥ 2 GI toxicity only occurred in 4 (1.4%) patients. The 4-year EFS, bPFS, DSS, and OS were 81.0%, 86.9%, 99.6% and 97.2%, respectively. CONCLUSIONS: Postoperative MHRT for PC demonstrates acceptable toxicity and promising efficacy. However, late GU toxicities continue to evolve beyond the 2-year period. Our findings identify key predictors: limiting bladder V60Gy may mitigate hematuria, and preRT incontinence predicts worsening UI.
引用
- Ren XY, Qin SB, Liu C, et al. Long-term Outcomes of Toxicities and Disease Control Following Postoperative Moderately Hypofractionated Radiotherapy in High-Risk Prostate Cancer: Results of a Prospective Study. Clin Transl Radiat Oncol. 2026. PMID: 41948198. doi:10.1016/j.ctro.2026.101150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。